According to Hologic, the NovaSure system is designed to apply radiofrequency energy to the endometrium and gently remove the lining of the uterus in two minutes or less.
The new system offers customers a smaller diameter (6mm) ablation device and an advanced interactive touchscreen radiofrequency controller. The Company expects a full market release in both the domestic and international markets for the new NovaSure 6mm device in December 2014.
Hologic said the NovaSure product enhancements are designed to improve patient comfort and physician ease-of-use while maintaining the clinical efficacy of the system.
The new 6mm device requires less dilation and is designed to improve patient comfort - especially for patients under local anesthesia and/or paracervical block in-office. An advanced radiofrequency touchscreen controller provides physicians with procedural instructions on the controller interface along with an ablation timer and procedural summary screen.
Hologic said the NovaSure system is used to treat women with abnormal uterine bleeding or heavy periods, a condition that affects one in five women 35-49 years old.
NovaSure endometrial ablation is a one-time, five-minute procedure that can be done in the doctor's office. To date over 2 million women have chosen the NovaSure procedure to treat the problem of lifestyle-restricting menstrual periods.
Find out more at www.hologic.com.
Perrigo to acquire United States rights for Entocort from AstraZeneca
US FDA approves Boehringer Ingelheim's Pradaxa
Phase II clinical trial for potential treatment of androgenetic alopecia completed by Samumed
Life Sciences Partners collaborates on immuno-oncology with Bristol-Myers Squibb
Arsanis initiates first cohort in Phase one clinical trial of ASN100
Impax introduces generic Avodart (Dutasteride) Capsules, 0.5 mg
Mylan unveils generic FazaClo orally disintegrating tablets for treating schizophrenia